GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Shiller PE Ratio

Nektar Therapeutics (LTS:0UNL) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Nektar Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Shiller PE Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nektar Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Shiller PE Ratio falls into.



Nektar Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nektar Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Nektar Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.18/133.0289*133.0289
=-0.180

Current CPI (Sep. 2024) = 133.0289.

Nektar Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.350 99.070 -0.470
201503 0.250 99.621 0.334
201506 -0.400 100.684 -0.529
201509 -0.060 100.392 -0.080
201512 -0.400 99.792 -0.533
201603 -0.140 100.470 -0.185
201606 -0.360 101.688 -0.471
201609 -0.320 101.861 -0.418
201612 -0.280 101.863 -0.366
201703 -0.420 102.862 -0.543
201706 -0.390 103.349 -0.502
201709 0.370 104.136 0.473
201712 -0.210 104.011 -0.269
201803 -0.600 105.290 -0.758
201806 5.330 106.317 6.669
201809 -0.560 106.507 -0.699
201812 -0.570 105.998 -0.715
201903 -0.690 107.251 -0.856
201906 -0.630 108.070 -0.776
201909 -0.560 108.329 -0.688
201912 -0.640 108.420 -0.785
202003 -0.780 108.902 -0.953
202006 -0.450 108.767 -0.550
202009 -0.610 109.815 -0.739
202012 -0.650 109.897 -0.787
202103 -0.680 111.754 -0.809
202106 -0.690 114.631 -0.801
202109 -0.700 115.734 -0.805
202112 -0.790 117.630 -0.893
202203 -0.490 121.301 -0.537
202206 -0.850 125.017 -0.904
202209 -0.310 125.227 -0.329
202212 -0.320 125.222 -0.340
202303 -0.730 127.348 -0.763
202306 -0.270 128.729 -0.279
202309 -0.240 129.860 -0.246
202312 -0.220 129.419 -0.226
202403 -0.190 131.776 -0.192
202406 -0.250 132.554 -0.251
202409 -0.180 133.029 -0.180

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (LTS:0UNL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nektar Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Nektar Therapeutics Headlines

No Headlines